Navigation Links
Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
Date:11/12/2009

l HE3286-0301

This Phase I/II trial explored the safety, tolerability and early signs of activity in chronic UC patients who were experiencing an acute flare in their disease. Patients were dosed for 28 days at 3 dose levels: 5 mg, 10 mg (5 bid) and 20 mg (10 bid) and Triolex was found to be safe and tolerable. Adverse events were mild to moderate and equally divided between Triolex and placebo-treated groups. The study was not powered to show statistically significant activity differences between placebo and drug-treated patients based on disease score changes. There was no clear separation between the placebo and active study arms over a one-month treatment period.

Rheumatoid arthritis Phase I safety, tolerance and drug compatibility study HE3286-0201

This Phase I safety and tolerance study was conducted in RA patients with stable disease that were concurrently taking methotrexate as maintenance therapy. A secondary objective of the study was to learn whether Triolex interfered with the action of methotrexate, which is required for concomitant dosing trials in patients with active disease. Three dose levels of Triolex were given daily to 14 subjects for 28 days along with weekly methotrexate. Three patients were dosed at 10 mg (5 mg bid), three at 20 mg (10 mg bid) and eight at 40 mg (2 mg bid) on an intent-to-treat basis.

Triolex was found to be safe and well tolerated. No disease flares or increased methotrexate toxicity were observed. Most adverse events were mild to moderate. Subject drug exposure remained dose proportional through the higher dose, and no change in methotrexate or Triolex pharmacokinetics was observed.

About Hollis-Eden Pharmaceuticals

Hollis-Eden Pharmaceuticals is a development-stage company with two product candidates in human clinical trials: Apoptone (HE3235), in the dose-escalation portion of a Phase I/II trial of patients with late-stage pros
'/>"/>

SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price
2. Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
3. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
4. NeoGenomics To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009
5. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
6. Viron to Present Data from Phase II Trial at American Heart Association Conference
7. Curemark Presents at Springboard Enterprises Life Sciences Forum
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
9. NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
10. CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
11. Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... quantum Hall effect in bilayer graphene and shown that ... an electric field. , The fractional quantum Hall ... sheets are exposed to large magnetic fields, is a ... electrons behave as a single system. However, while the ... details of this collective behavior remain not well understood, ...
(Date:7/10/2014)... recent study by researchers at the University of ... physical mechanisms governing the interplay of spin and ... limits of ultrafast spintronic devices for data storage ... charge as well as spin-angular momentum. In a ... there is no spin current," explained David Cahill, ...
(Date:1/15/2014)... , Jan. 15, 2014  Bill Jacobs Automotive, a group of ... teaming up with the Heartland Blood Center and offering free ... The drive takes place Saturday, Jan. 18 at the Bill ... p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The ...
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused ... analysis of tumor cells in the bloodstream, today announced ... decision support application powered by CollabRx, Inc. , ... test, Therapy Finder will provide breast cancer patients and ...
Breaking Biology Technology:Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3University of Illinois study advances limits for ultrafast nano-devices 2Join the Bill Jacobs Auto blood drive and receive a free oil change 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3
... Accera, Inc., a biotech company specializing in ... to the Alzheimer,s Foundation of America (AFA) for sponsorship ... Alzheimer,s Disease Awareness Month.  These funds will be used ... individuals with Alzheimer,s disease (AD) and their families, especially ...
... SHELTON, Conn., Oct. 24, 2011 Modern Plastics, one ... shapes and medical-grade plastics, has become ISO 13485-2003 certified ... Tube, Film and Resin. "This is ... customer commitment to service and quality," said Bing J. ...
... Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in ... the European Medicines Agency,s (EMA) Committee for Medicinal Products ... that Glybera (alipogene tiparvovec) is not approvable at this ... recommendation of CHMP Rapporteurs, the Scientific Advisory Group (SAG), ...
Cached Biology Technology:Accera, Inc. Donates $50,000 to the Alzheimer's Foundation of America for National Memory Screening Day 2Accera, Inc. Donates $50,000 to the Alzheimer's Foundation of America for National Memory Screening Day 3Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application 2Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application 3
(Date:7/10/2014)... COMMACK, N.Y. , July 2, 2014 ... Inc. (ABD) to announce the appointment of the world-renowned ... its Board of Directors. Dr. Ginsburg, with ... two facilities: NY Presbyterian Hospital and Good Samaritan Regional ... Breathing Pacemaker since the late 1980,s and is considered ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) has ... Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, ... to their offering http://photos.prnewswire.com/prnh/20130307/600769 ... Sensing Market to Grow Exponentially. Touch-less sensing applications ... companies were unable to leverage this technology due ...
(Date:7/10/2014)... 2014 Fingerprint Cards, (FPC,s) ... win (DW). An Asian OEM has selected FPC1021 for a ... in August 2014.   FPC is proud to ... a planned date for start of mass production in August ... SEK 5M, for delivery in the first half of July. ...
Breaking Biology News(10 mins):Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... This release is available in German . ... or malaria treatment could soon become easier - thanks to ... Institute of Molecular Physiology in Dortmund aim to facilitate the ... Scaffold Hunter, acts as a tool for navigating chemical space. ...
... Palo Alto, CAWith the information explosion, it,s ... interactions that proteins have with each other and ... interactive, so-called membrane proteins regulate nutrients and water ... interface with neighboring cells and within the cell. ...
... generates electricity can also remove 90 percent of salt from ... researchers from China and the U.S. Clean water for ... some parts of the world. Its availability in the future ... using either a reverse osmosis process -- one that pushes ...
Cached Biology News:Navigating in the ocean of molecules 2Navigating in the ocean of molecules 3Carnegie donates landmark clones to biology 2Wastewater produces electricity and desalinates water 2Wastewater produces electricity and desalinates water 3
... E-PAGE Gels easier and more efficient by ... several types of pre-cut pre-assembled membrane/filter paper ... 13.5 cm E-PAGE Gels*. The available nitrocellulose ... western transfer of proteins (Figure 1 Table ...
... carbohydrate analysis standard is a lyophilized ... sugar alcohol; molecular weights range from ... provided for use with the Aminex ... kit for column testing or semiquantitative ...
... kit was tested on rat tissue extracts (liver, ... ( S. cerevisae ) extract. It was also ... and cell lines. Application: A simple and reliable ... based on the detection of the inorganic phosphate ...
... is the condition in which a lack ... and the various antioxidants. Oxidative stress ... of several diseases, including artherosclerosis, chronic inflammatory ... several antioxidant systems that are very important ...
Biology Products: